PharmaMar has announced today the signing of a commercialization and distribution license agreement with Pint Pharma International for the marine-derived anticancer drug Aplidin (plitidepsin) in Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, Paraguay, Peru, Uruguay, and Venezuela.
According to the agreement, Pint will pay undisclosed milestone and royalty payments to PharmaMar in exchange for the rights to register, commercialize and distribute Aplidin in each of the foresaid territories. PharmaMar will retain exclusive production rights and will supply the finished product for clinical and commercial use.
The company announced at the ASH Congress during December 2017, in San Diego, the results in a pivotal Phase III clinical trial (ADMYRE) with plitidepsin, where the primary endpoint, progression free survival, and secondary objectives, overall survival and safety were met; providing the treatment for multiple myeloma with a novel mechanism of action.
"We are about to address our first strategic alliance with Pint Pharma International for the commercialization of Aplidin, developed to tackle Multiple Myeloma,” Luis Mora, Managing Director of Pharma Mar's Oncology Business Unit said. “This agreement is aligned with our commitment to bring novel and first-in-class therapies to patients worldwide."